相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
Oleg Fedorov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Ultan McDermott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity
Giovanni Solinas et al.
CELL METABOLISM (2007)
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
Robyn P. Araujo et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
Charles A. Schiffer
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice
Mansuo L. Hayashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Regulation of mitosis via mitotic kinases: new opportunities for cancer management
Travis L. Schmit et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis
Leonard Buckbinder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Integrative genomic approaches identify IKBKE as a breast cancer oncogene
Jesse S. Boehm et al.
CELL (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation
Nupam P. Mahajan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Targeting checkpoint kinase 1 in cancer therapeutics
Archie N. Tse et al.
CLINICAL CANCER RESEARCH (2007)
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
Mark G. Manfredi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Opinion - Why is cancer drug discovery so difficult?
Alexander Kamb et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Sorafenib in renal cell carcinoma
Keith T. Flaherty
CLINICAL CANCER RESEARCH (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Henk. M. W. Verheul et al.
NATURE REVIEWS CANCER (2007)
New approaches to molecular cancer therapeutics
Ian Collins et al.
NATURE CHEMICAL BIOLOGY (2006)
Structure and chemical inhibition of the RET tyrosine kinase domain
Phillip P. Knowles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
PI3Kγ inhibition:: towards an 'aspirin of the 21st century'?
Thomas Rueckle et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Wanli W. Smith et al.
NATURE NEUROSCIENCE (2006)
Systems biology and combination therapy in the quest for clinical efficacy
Jonathan B. Fitzgerald et al.
NATURE CHEMICAL BIOLOGY (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Validating cancer drug targets
John D. Benson et al.
NATURE (2006)
Mechanisms of drug inhibition of signalling molecules
Judith S. Sebolt-Leopold et al.
NATURE (2006)
Evolution of the thienopyridine class of inhibitors of IκB kinase-β:: Part I:: Hit-to-lead strategies
Tina Morwick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Altered bone and mineral metabolism in patients receiving imatinib mesylate
E Berman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors
NM Heron et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
An efficient rapid system for profiling the cellular activities of molecular libraries
JS Melnick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease
KA Whartenby et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Discovery of a 1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity
M Wittman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Roscovitine targets, protein kinases and pyridoxal kinase
S Bach et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
Pathway to the clinic: Inhibition of p38 MAP kinase. A review of ten chemotypes selected for development
DM Goldstein et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
Kinomics-structural biology and chemogenomics of kinase inhibitors and targets
M Vieth et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Creating chemical diversity to target protein kinases
B Li et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
3-aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding
P Pevarello et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
PS Changelian et al.
SCIENCE (2003)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family
A Pandey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
C Pargellis et al.
NATURE STRUCTURAL BIOLOGY (2002)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)